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Abstract: The causes and degree of line (Zn)
deficiency in uraemia arc still comroversal. The
effect of different treatment modalities are still
unseneled. Plasma Zn represent only a small part of
the total body Zn (about O.5o/t-). Thus determination
of intracellular Zn in the peripheral blood cells might
be more reliable. The present study was designed to
assess the actual Zn status ill uraemia and to find
whether the treatment modalities of eRF
(conservative and dialytic) could influence Zn status.
Also to determine the elfeet of single dialysis
session, type of dialysis and dialysate buffer on the
Zn status.
This study included ten healthy controls and Iourty
eRF patients divided in three subgroups on different
treatment modalities IlO conservative treatment, 15
on intermittent perioncal dialysis ((I'D) and 15 on
haemedialysis (lID) I.
:I.nic was measured hv atomic absorption
scpcctrophotomctry in plasma and platclcts.
Statistically xignificam decrease of plasma /11 and
significant increase or platelet Zn were found in eRF
patients on dillerent treatment modalities as
compared to controls (P«l.O I), hut there was no
significant difference In this respect hetween the
three urucnuc subgroups. There was no di Ilcrcncc as
regard serum protein and albunun levels in urnmie
subgroups compared to controls. Morcover plasma
Zn was significantly increased (sï ill less than control)
and platelet Zn was significantly decreased (P<O.OI)
after a single dialysis session in both IPl) and liD
subgroups, hut the changes of both parameters
(before and alter dialysrs) were insignificant in IPI)
patients compared to HI) patients.
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Significant negative correlation was found between
platelet Zn and creatinine clearance in the three
uraemic subgroups (r = -0.81 P<O.Ol in conservative
patients, r= -0.72 P<O.OI in IPD and r= -0.76 P<O.OI
in HD) while no correlation could be detected
between the duration of dialysis and each of platelet
& plasma Zn and between and plasma Zn and each of
platelet Zn, serurn creatinine and clearance. Plasma
Zn showed transient significant rise in HD patients
using bicarbonate (11.6± I. I Il mol/L) as compared to
those using acetate buffer (9.1± l.3 Il mol/LJ, P<O.Ol).
We can conclude that intracellular measurements of
Zn (platelet) is of value in diagnosis and monitoring
of Zn .status in uraemics. Different treatment
modalities does not influence Zn haernostasis. with
110 superiority of particular type of dialysis in this
respect. The effect of a single dialysis session and the
lise of bicarbonate versus acetate buffer was just a
transient rise of plasma Zn due to
hacrnoconcentration and better correction of acidosis
during dialysis.
Introduction
Zinc (Zn) is present In a large number of proteins and
enzymes, c.g. metallo-thiorune and DNA-hinding
proteins. It is essential for gene expression, growth
hormone activity, cellular signal transduction, neuro-
transmitter receptors and membrane functions [241. It
had been reported that uraemic patients have
ubnormal Zn metabolism [16]. The change in Zn
metabolism may be responsible for certain features of
uraemia 1181. These features include gonadal
dysfunction 1141, hyperprolactinaernia [131 and
neuropathy 121 I.
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The causes and degree of Zn deficiency in uraemia
are controversal, it may be due to decreased Zn
absorption [I] due to specific Zn transport defect or
the absence of intestinal Zn ligands as picolinic acid
[ 16].
Zn is usually measured in plasma or serum as it is
easily accessible and relatively simple to process.
However, plasma values represent only a small
percentage (1-2%) of body content.
Determination of plasma Zn does not provide
conclusive evidence of Zn deficiency [20]. Thus
diagnosis of mild and moderate Zn deficiency is still
an unsolved problem and increased attention should
be devoted to the intracellular measurement in
erythrocyte (which contain 85%), platelet and
leucocytes which represent tissue Zn [6]. Red blood
cells (RBCs) have slow turnover, thus Zn content
does not rellect current Zn status and platelet Zn is a
more reliable index of short term changes [19].
This study was designed to assess the actual Zn
status in uraemia and to find out whether treatment
modalities of CRF (conservative and dialytic)
influence Zn haemostasis. Also to determine the
effect of single dialysis session, type of dialysis and
dialysate buffer (bicarbonate and acetate) on the Zn
status.
Materials and methods
This study was carried out in the Internal Medicine
(Nephrology Unit) and the Clinical Pathology
Departments, Zagazig University Hospitals.
Subjects
We included fifty subjects in this work, they were
divided into:
J. Control group: It comprised ten adult healthy
volunteers (six males & four females), their ages
ranged from 19-65 years with a mean of 41.3±
I 1.3 years. They had normal renal functions.
Il. Chronic renal failure (CRF) group: It included
fourty patients divided into three subgroups
according to the line of treatment:
• Conservative subgroup: Ten patients (six
males & four females) with CRF, their ages
ranged from 31-63 years with a mean of 43.71 ±
13.3 years. They were on conservative
treatment for five months to two years. The
etiology of CRF was glomerulonephritis in
four patients and chronic pyelonphritis in six
patients. The mean serum creatinine was (4.6±
0.72 mg%-).
• Peritoneal dialysis subgroups ([PD): It
included 15 CRF patients (nine males & six
females), their ages ranged from 16-56 years
with a mean of 44.4± 12.1 years. Duration of
dialysis ranged from 6-30 months with a mean
of 14.5± 1.5 months (8 of them were dialysed
for more than one year). IPD was performed
twice weekly with thirty liters each session.
None of (PD patients was previously treated
by haemedialysis. The etiology of CRF was
chronic pyelonephritis in ten patients and
chronic glomerulonephritis in five patients.
• Haemedialysis subgroup (HD): It comprised
15 patients (eleven males & four females),
their ages ranged from 16-66 years with a
mean of 39.5± 14.2 years. HD was performed
twice weekly, each session lasted for 4-6
hours, 8 of them used bicarbonate buffer and
the other seven patients used acetate buffer.
Only cuprophane low-flux (surface area I-I)
E2 dialysers were used. The duration of
dialysis ranged from 7-42 months, with a
mean of 18± 3.1 months, (8 of them were
dialysed for more than one year). The
etiology of CRF was chronic pyelonephritis in
eleven patients and chronic glorncrulo-nehritis
in 4 patients.
All patients in this study were selected to be free from
diabetes, hepatic diseases and malignancy and were
on recommended diet for uracrnics. Those receiving
erythropoeitin or vit D therapy were also excluded.
All cases were in stable condition and had no
advanced complications. Patient data are shown in
table I.
Table 1. Clinical data of the different groups:
Control group Conservative group !P!) gml/p !!/)/irrJI/P
Age (years) 41.3:111.3 43.7jl3.3 44.4jI2.1 39.5jI4.2
Sex (M/F) 614 6/4 9/6 I 1/4
Duration of dialysis (months) 14.5jl.5 1833.1
Hb% (gm%) 14jl.3 9.5j1.01 8.5:lO.99 8.92j1.03
Total protein (g/L) 8.1:JO.91 7.7:JO.72 7.6:lO.63 7.9jO.58
Serum albumin (g/L) 4.5:JO.44 3.9:JO.33I 3.8:lO.40 4.1j() 39
S. creatinine (mgo/c) 0.9:JO.03 4.6:JO.72 8.2:lO.9 6.57:lO.61
Creatinine clearance (ml/min) 93:16.3 11.4:JO.88 6.4:lO.46 8.4j().62
Methods
All subjects in this study were submitted to the
following:
A. Thorough history and clinical examination.
B. Routine investigations including:
• Urine analysis.
• Complete blood count, packed cell volume.
platelet count and platelet indices using
sysmex cell counter model 3000.
• Liver function tests especially total proteins
and serum albumin and screening tests for
HbsAg and HCV antibodies.
• Kidney function tests: blood urea. serum
creatinine and creatinine clearance by
standard methods.
• Fasting and 2h blood glucose.
• X-ray chest and abdominal sonogram.
C. Specific test: Measurement of pluvrna and platelet
zinc. After separation of platelet. line content \\'a~
measured in both plasma and platelet h~ alomie
absorption spccuo-photomctcrx II) I.
Principle ofassav
The samples were centrifuged (12()()g I() min) and
their supernatcrux were carclull~ a\pir;lIcd. We then
added 3 ml of undiluted nitric .urd lo the iubc-, und
the samples were heated ;1113) C III ,I blue], heater
until only a residue remained. ï hi, treurment II ith
acid was repeated twice.
After the samples were digested. IlL' added c xuctly I
ml of a 10 milL solution of nitric acid to dissolve rhc
mineral salts. Zinc contenlof both pluteler und plasma
samples was determined by atomic absorption
spectrophotometry (Perkin-Elmer. Model 31 10) and
appropriate zinc standards.
N.B: Samples for plasma and platelet Zn were
obtained belore and after the dialysis session in
patients under dialysis treatment, but onee in
conservatively treated patients and control subjects.
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Results
A statistically significant increase in platelet count
and platelet Zn (P<O.Ol), and statistically
significant decrease in plasma Zn and packed cell
volume (PCV) (P<O.O I) were found in the three
uraemic subgroups (conservative. IPD & HD) as
compared to controls, while there was no
significant difference in the previous parameters
between the three uraemic subgroups.
Serum albumin showed no significant difference
between control group and all uraemic subgroups
and between each of the three uraemic subgroups
as shown in table 2.
A statisticaly significant increase in plasma Zn and
PCV (P<O.O I) and significant decrease in platelet
Zn (P<O.O I) in IPD and HD subgroups after single
session of dialysis was found. Platelet count was
significantly increased after single dialysis session
only in HD patients (P<O.O I) as shown in table 3.
The change (Ll) in the levels of platelet and plasma
Zn after single dialysis session (the difference in
the between pre and post dialysis values) were not
significant in IPD patients compared to HD
subgroup as shown in table 4.
Plasma Zn was significantly increased in HD
subgroup using bicarbonate buffer as compared to
those using acetate buffer (P<O.OI). The rise was
transient after single dialysis session, while there
was no significant difference in the platelet Zn in
acetate buffered HD patients as compared to
bicarbonate buffered HO patients as in table 5.
A statistically significant negative correlation
between platelet Zn and creatinine clearance was
observed in the all uraemic subgroups (r=-0.81.
P<O.OI in conservative patients. r = - 0.72. P<O.OI
in IPD and r=-0.76, P<O.O I in HD patients). No
significant correlation could be detected between
plasma Zn and each of platelets Zn and creatinine
clearance in the three uraemic subgroups similarly
between duration of dialysis and each of platelet
and plasma Zn in dialytic subgroups as shown in
table 6.
'ruble 2. Comparison or the mean values JSD or plate lei count, plasma & platlet zinc packed ccII volurne (PCV) and serurn albumin in
different groups
ClJlIll'IIlg/'OujI Conservative sroup IPD HJ) F P
Platelet count (x I0") 243.IJI12.2 340.3j 176.2 356.ljI80.1 372. tj204. t 7.693 <0.01
Plasma Zn (jmol/L) 14.1J1.6 9.62JI.3 9.93:H.4 10.06j2.I 14.332 <0.01
Ploteler Znfrunol/! 0" cells) 190.8.194.3 329.7j215.4 329.9j218.9 309:!206.2 9.82 <0.01
PCV(%) 43.9:14.2 3 t.6:J..1.3 31.5:14.2 30.2:14.2 18.37 <0.01
Serurn albumin (gIL) . 4.5jO.44 3.9:10.331 3.8:!O.40I 4. I:!O39 0.07t NS
H = Significant in comparison to control group. b = Significant in comparison lO conservative group.
c = Significant in comparison 10 IPD group.
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Table 3. Comparison of the mean values :lSD of platelet count and zinc, plasma zinc and PCY in IPO and HO group before and after one
dialysis session
IPD HD
Before after T p before after p
Platelet count Cx 10') 356.1:l180.1 361.9:l193 1.145 NS 372.1 :l204.1 411.2:l197.4 6.921 <0.01
Plasma Zn (jmol/L) 9.43:l1.4 10.9:l1.2 9.22 <0.01 lO.06:l2.1 I 1.02:l2.4 6.934 <0.01
Platelet Zn(nmol/I a' cells) 329.9:l218.9 299.5:l21 I.9 10.82 <0.01 309:l206.2 282.5:l200.3 7.63 <0.01
PCY (0/0) 31.5:l4.2 34.2£.4 5.056 <0.01 30.2:l4.3 36.3:l3.2 5.99 <0.01
Table 4. Mean values :lSD of changes CL)in the levels of platelet and plasma zinc in IPO and HO groups after single dialysis session
IPD PHD
L of plasma zinc (pnol/L)









Table S. Comparison of the mean value:lSO of plasma and platelet line in HO subgroup using acetate versus bicarbonate buffer
HD using acetate (11=8) PHD using bicarbonate (,,=7)
Plasma zinc (jmol/L)









Table 6. Correlation coefficient between platelet and plasma zinc and the different parameters in the three uraemic subgroups
Variable Conservative group IPIJ HIJ
P P il
-0.36 NS -0.33 NS -0.27 NS
-0.24 NS -0.23 NS -0.31 NS
0.33 NS 0.34 NS 0.28 NS
0.31 NS 0.18 NS
-0.22 NS -0.17 NS -0.19 NS
-0.81 <0.01 -o.n <0.01 -0.76 <0.01
0.14 N.S. 0.26 N.S
Plasma Zn versus platelet Zn
Plasma Zn versus platelet count
Plasma Zn versus creatinine clearance
Plasma Zn versus duration of dialysis
Platelet Zn versus platlet count
Platelet Zn versus creatinine clearance
Platelet Zn versus duration of dialysis
Discussion
Zn is an essential component of a large number of
metalloenzymes and is important for normal
metabolism in man [6]. It had been reported that
patients with chronic renal failure have an abnormal
zinc metabolism [16]. These changes in Zn
metabolism may account for certain feature of
uraemia [18].
In the present study serum albumin and protein did
not show any difference in the three uraemic
subgroups ascompared to controls, which exclude the
effect of hypoalbuminaernia in Zn haemostosis.
Plasma Zn levels were significantly lower is uraemic
patients under different treatment modalities
(conservative, [PD and HD) compared to control,
indicating deficiency of circulating Zn in uraemics.
Similar results were obtained by others 111,20,251.
Paniagua et al. [161 attributed low circulating Zn
level in uraemia to low Zn intake, a specific Zn
transport defect or absenceof specific Zn ligands.
Other studies suggested impaired absorption [81.
Several factors are thought to be involved in
malabsorption aschronic enteritides and excessive
losses (five times higher than the uptake of Zn may
occur) [2]. Impaired tubular reabsorpation caused
by the uraemic milieu was also suspected[23].
The low plasma Zn levels in the three uraemic
subgroups in this study denote failure of any
treatment modality to correct circulating Zn level. The
absence of correlation between plasma zinc and
duration of dialysis in dialytic subgroups and non
significant difference of plasma Zn between the
uraemic subgroups and each other indicate failure of
dialytic therapy (fPO & HO) to correct plasma Zn.
This is in agreement with the results obtained by
Karninska - Galwa et al. 171 who found low plasma
Zn level in uraernics, which was similar in both short
and long term dialysis groups.
It seems impossible to diagnose Zn deficiency by
plasma level only, as it accounts for 1-2% of the
entire pool, the largest amount of Zn is present
intracellularly. Erythrocytes contain (85%) 19], but it
has slow turn over and does not reflect current Zn
status, while platelets have an average life span 7-10
days and its Zn content could be a more reliable index
of short term changes in Zn status [19,20 J.
In this study platelet Zn was significantly higher in
the three uraemic subgroups compared to controls.
This result was supported by previous results obtained
by Schmitt 1201 who found that Zn is elevated in
erythrocytes and platelets of uremies. These findings
may be explained by abnormal shift of Zn from
plasma to the intracellular compartmcnt IZê].
These results point to change in distribution of Zn in
uracmics resulting in decreased plasma Zn and
increased intracellular zinc (platelet). So in uraemic
patients we can not depend on plasma zinc level to
diagnose Zn deficiency. This concept could be
illustrated by a study done by Chen & Yang 13] who
found that platelet Zn was similar in uremies and
controls but in the same study plasma Zn was
markedly low indicating severe deficiency.
In view of the above results intracellular Zn is a more
reliable index for diagnosis and monitoring of Zn
status than plasma Zn.
Platelet Zn was negatively correlated with creatinine
clearance in our uraemic subgroups but plasma Zn
was not, indicating the close relation between tissue
Zn (platelet) and degree of renal impairment.
Ilowever there was no correlation between plasma
and platelet Zn in the different studied subgroups.
These results were supported by those of lotova et al.
161. Hinks ct al. 151 recommended measurement of
erythrocyte Zn content in order to determine the long
term Zn status. For assessment of acute changes,
leukocytes might be more suitable not only because of
their shorter life span, but because they are nucleated,
metabolically more active and thus more rcprcsentive
of other body compartments [4,171.
After a single dialysis session we found that plasma
Zn was significantly higher in both dialytic subgroups
compared to their values before the session, however,
levels were still significantly lower than controls. This
elevation was in agreement with the result obtained
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by Lin et al. [II]. It may be due to
haemoconcentration as packed cell volume (PCV)
was also significantly higher after the dialysis
session although it was still lower than that of
controls [6]. Platelet Zn was significantly
decreased after the dialysis session compared to
their values before dialysis in the two dialytic
subgroups in our study. Similar results were
obtained by Iotova et al. [6] and this transient
change may be attributed to changes that occur
during dialysis as redistribution of Zn from platelet
to plasma or to the increased platelet count as we
found III our patients during hemodialysis
secondary to the effect of anticoagulants. We also
found that there was no significant difference
between the change in Zn status (plasma &
platelet) in patients under HD in comparison to
those under peritonial dialysis, indicating no
superiority of either type of dialysis for correction
of Zn status in CRF. Meanwhile plasma but not
platelet Zn was transiently and significantly
increased in patients on bicarbonate haemodialysis
compared to those using acetate buffer. This
finding was confirmed by Iotova et al. [6], denoting
a more beneficial effect of bicarbonate buffer for
correction of acidosis with subsequent
improvement of Zn absorption.
We can conclude that intracellular measurrnent of
Zn (platelet) is of value for diagnosis and
monitoring of Zn deficiency states in uraemics.
Furthermore treatment modalities of CRF do not
influence Zn haemeostasis, with no superiority for
a particular type of dialysis in this respect. A single
dialysis session and the LIseof bicarbonate buffer
caused transient elevation of plasma zinc, due to
hemoconcentration and beuer correction of
acidosis respectively that occur during dialysis.
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